Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Allergy Clin Immunol ; 148(3): 813-821.e7, 2021 09.
Artigo em Inglês | MEDLINE | ID: mdl-33865872

RESUMO

BACKGROUND: Hereditary alpha-tryptasemia (HαT) is characterized by elevated basal serum tryptase due to increased copies of the TPSAB1 gene. Individuals with HαT frequently present with multisystem complaints, including anaphylaxis and seemingly functional gastrointestinal (GI) symptoms. OBJECTIVE: We sought to determine the prevalence of HαT in an irritable bowel syndrome cohort and associated immunologic characteristics that may distinguish patients with HαT from patients without HαT. METHODS: Tryptase genotyping by droplet digital PCR, flow cytometry, cytometry by time-of-flight, immunohistochemistry, and other molecular biology techniques was used. RESULTS: HαT prevalence in a large irritable bowel syndrome cohort was 5% (N = 8/158). Immunophenotyping of HαT PBMCs (N ≥ 27) revealed increased total and class-switched memory B cells. In the small bowel, expansion of tissue mast cells with expression of CD203c, HLA-DR, and FcεRI, higher intestinal epithelial cell pyroptosis, and increased class-switched memory B cells were observed. IgG profiles in sera from individuals with HαT (N = 21) significantly differed from those in individuals with quiescent Crohn disease (N = 20) and non-HαT controls (N = 19), with increased antibodies directed against GI-associated proteins identified in individuals with HαT. CONCLUSIONS: Increased mast cell number and intestinal epithelial cell pyroptosis in the small intestine, and class-switched memory B cells in both the gut and peripheral blood associated with IgG reactive to GI-related proteins, distinguish HαT from functional GI disease. These innate and adaptive immunologic findings identified in association with HαT are suggestive of subclinical intestinal inflammation in symptomatic individuals.


Assuntos
Gastroenteropatias , Doenças Genéticas Inatas , Imunoglobulina G/imunologia , Intestino Delgado/imunologia , Mastocitose , Triptases , Adulto , Células Epiteliais/imunologia , Feminino , Gastroenteropatias/sangue , Gastroenteropatias/genética , Gastroenteropatias/imunologia , Gastroenteropatias/patologia , Doenças Genéticas Inatas/sangue , Doenças Genéticas Inatas/genética , Doenças Genéticas Inatas/imunologia , Doenças Genéticas Inatas/patologia , Genótipo , Humanos , Imunoglobulina G/sangue , Intestino Delgado/citologia , Intestino Delgado/patologia , Masculino , Mastócitos/imunologia , Mastocitose/sangue , Mastocitose/genética , Mastocitose/imunologia , Mastocitose/patologia , Pessoa de Meia-Idade , Piroptose , Triptases/sangue , Triptases/genética , Adulto Jovem
2.
FASEB Bioadv ; 1(10): 624-638, 2019 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-31803861

RESUMO

Exosomes are nano-sized vesicles that are involved in various biological processes including cell differentiation, proliferation, signaling, and intercellular communication. Urinary exosomes were isolated from a cohort of hereditary α-tryptasemia (HαT) patients and from healthy volunteers. There was a greater number of exosomes isolated from the urine in the HαT group compared to the control volunteers. Here, we investigated the differences in both lipid classes and lipid species within urinary exosomes of the two groups. Lipids were extracted from urinary exosomes and subjected to liquid chromatography mass spectrometry using a targeted approach. Various molecular species of glycerophospholipids, glycerolipids, and sterols were significantly reduced in HαT patients. Out of a possible 1127 lipids, 521 lipid species were detected, and relative quantities were calculated. Sixty-four lipids were significantly reduced in urinary exosomes of HαT patients compared to controls. All significantly reduced sphingolipids and most of the phospholipids were saturated or mono-unsaturated lipids. These results suggest exosome secretion is augmented in HαT patients and the lipids within these exosomes may be involved in various biological processes. The unique lipid composition of urinary exosomes from HαT patients will contribute to our understanding of the biochemistry of this disease.

3.
Sci Rep ; 8(1): 10652, 2018 Jul 13.
Artigo em Inglês | MEDLINE | ID: mdl-30006637

RESUMO

Therapy of Burkholderia pseudomallei acute infections is largely limited to a few ß-lactam antibiotics such as ceftazidime or meropenem. Although relatively rare, resistance emergence during therapy leads to treatment failures with high mortality rates. In the absence of acquired external resistance determinants in B. pseudomallei emergence of ß-lactam resistance is invariably caused by mutational modification of genomically encoded factors. These include the deletion of the ceftazidime target penicillin-binding protein 3 or amino acid changes in the Class A PenA ß-lactamase that expand its substrate spectrum, as well as penA gene duplication and amplification or its overexpression via transcriptional up-regulation. Evidence is presented that penA is co-transcribed with the upstream nlpD1 gene, that the transcriptional terminator for nlpD1 serves as a penA attenuator and that generation of a new promoter immediately upstream of the terminator/attenuator by a conserved G to A transition leads to anti-termination and thus constitutive PenA expression and extended ß-lactam resistance. Further evidence obtained with the extensively ß-lactam resistant clinical isolate Bp1651 shows that in addition to PenA overexpression and structural mutations other adaptive mechanisms contribute to intrinsic and acquired B. pseudomallei ß-lactam resistance.


Assuntos
Antibacterianos/farmacologia , Proteínas de Bactérias/genética , Burkholderia pseudomallei/genética , Lipoproteínas/genética , Melioidose/tratamento farmacológico , Resistência beta-Lactâmica/genética , beta-Lactamases/genética , Antibacterianos/uso terapêutico , Proteínas de Bactérias/metabolismo , Burkholderia pseudomallei/efeitos dos fármacos , Ceftazidima/farmacologia , Ceftazidima/uso terapêutico , Duplicação Gênica/efeitos dos fármacos , Regulação Bacteriana da Expressão Gênica/efeitos dos fármacos , Regulação Bacteriana da Expressão Gênica/genética , Genes Bacterianos/efeitos dos fármacos , Genes Bacterianos/genética , Interações Hospedeiro-Patógeno/genética , Humanos , Lipoproteínas/metabolismo , Melioidose/microbiologia , Meropeném/uso terapêutico , Testes de Sensibilidade Microbiana , Mutação/efeitos dos fármacos , Regiões Promotoras Genéticas/genética , Processamento Pós-Transcricional do RNA , RNA Bacteriano/genética , Regulação para Cima/efeitos dos fármacos , Resistência beta-Lactâmica/efeitos dos fármacos , beta-Lactamases/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA